中文摘要：

雄激素受体（androgen receptor,AR）在前列腺癌的发生发展中扮演重要角色.雄激素剥夺疗法（androgen deprivation therapy,ADT）早期可成功抑制肿瘤的生长,但最终导致肿瘤复发并进入激素抵抗阶段.AR对前列腺癌基质细胞起促进肿瘤增殖和转移作用,是上皮腔样细胞的存活因子,而对肿瘤干细胞样细胞及上皮基底细胞的增殖起抑制作用,AR在不同类型细胞中的不同作用向当前ADT传统的疗法提出挑战,为发展新的治疗策略提供理论依据.目前以AR为靶点的靶向治疗药物研发也取得一些进展.本文就AR在前列腺癌不同类型细胞中的作用及靶向治疗方面的进展加以综述.

英文摘要：

Androgen receptors （AR） have an important function in the development and progression of prostate cancer. Andro-gen deprivation therapy （ADT） is successful in suppressing prostate tumor growth;however, the therapy eventually fails, leading to re-current tumor growth in a hormone-refractory manner. Recent studies indicate that AR acts as a proliferation stimulator for prostatic stromal cells, whereas epithelial AR functions as a survival factor for luminal cells and a suppressor for tumor stem-like cells and epithe-lial basal cells proliferation. The varying functions of different AR cell types present a severe challenge for current ADT, but provide im-portant bases for treatment strategies. Significant progress has been achieved in targeted therapy for prostate cancer through AR. This ar-ticle reviews the research developments in the role of AR in the different types of prostate cancer cells and in targeted therapy.